Chai

Chai is an artificial intelligence and biotechnology company that utilizes advanced machine learning models to design full-length monoclonal antibodies and accelerate pharmaceutical drug discovery. The venture-backed enterprise has successfully secured $130 million in Series B funding to scale its computational biology platform and therapeutics development initiatives across the biotechnology sector. Chai is supported by prominent institutional investors including OpenAI and General Catalyst, and the company recently appointed former Pfizer Chief Scientific Officer Mikael Dolsten to its board of directors. The firm's proprietary Chai-2 foundational model has demonstrated significant technical capabilities in computational antibody design, achieving an 85 percent success rate for proposing molecular hits that meet strict drug-like criteria. Chai was founded in 2023 by a core team including former OpenAI researcher Josh Meier, former Stripe executive Jack Dent, Matt McPartlon, and Jacques Boitreaud.

High-Level Overview

Chai Discovery is an AI company developing technology to predict and reprogram interactions between biochemical molecules, with a mission to transform biology from science into engineering.[2] It serves researchers, biotech firms, and drug developers by enabling a "computer-aided design suite" for molecules, solving the challenge of inefficient molecular discovery through AI-driven predictions and reprogramming.[2] The company has raised over $225 million in total funding, including a $130 million Series B in December 2025 valuing it at $1.3 billion, fueling research acceleration, product development, and commercialization.[2]

Chai Research, a distinct entity, builds a conversational AI platform allowing developers and consumers to create and interact with chatbots powered by large language models.[3][4] It targets app developers and end-users seeking customizable AI companions, addressing the need for accessible, interactive AI experiences. Note: Search results also reference a separate energy analytics firm called ChAI and an investment manager CHAI Trust Co LLC, but "Chai" most closely matches these AI-focused portfolio companies given the tech context.[1][5]

Origin Story

Chai Discovery emerged from pioneering research and applied AI companies, though specific founders are not detailed in available data; its team brings expertise in AI and biology.[2] The company gained momentum with a $130 million Series B in December 2025, co-led by Oak HC/FT and General Catalyst, bringing total funding to over $225 million and adding board members Annie Lamont and Hemant Taneja.[2] This round marks a pivotal shift toward scaling its molecular AI platform.

Chai Research launched as a technology company focused on conversational AI, with its platform enabling chatbot creation via large language models; founding details and early traction remain undisclosed in public records.[3][4] It operates in the pre-IPO space, attracting investor interest amid the generative AI boom.

Core Differentiators

Chai Discovery:

• AI-native molecular engineering: Predicts and reprograms biochemical interactions, shifting biology toward programmable design like CAD software for molecules.[2]
• Proven funding traction: $225M+ raised, including a unicorn valuation post-Series B, backed by healthcare-focused VCs like Oak HC/FT.[2]
• Expansion focus: Prioritizes R&D acceleration and commercialization to deliver practical tools for drug discovery and biotech.[2]

Chai Research:

• User-generated AI chatbots: Empowers non-experts to build and deploy conversational agents using LLMs, emphasizing interactivity.[3][4]
• Developer and consumer accessibility: Bridges creation tools for apps with direct consumer engagement, differentiating from enterprise-only platforms.[4]
• Pre-IPO growth potential: Positions in the conversational AI market with secondary market interest via platforms like Forge and Nasdaq Private Market.[3][4]

Role in the Broader Tech Landscape

Chai Discovery rides the AI-for-science wave, particularly in biotech, where generative AI accelerates drug discovery amid rising R&D costs and timelines—market forces like aging populations and precision medicine demand faster molecular insights.[2] Its timing aligns with 2025's AI investment surge in healthcare, influencing the ecosystem by enabling "biology as engineering," potentially cutting development cycles for partners in pharma and research.

Chai Research taps the conversational AI explosion, fueled by LLMs like those from OpenAI and Anthropic, serving a market projected to grow with consumer AI adoption.[3][4] It democratizes chatbot creation, boosting app ecosystems and competing in a space where timing favors accessible tools over siloed enterprise solutions, subtly shaping developer workflows and user-AI interactions.

Quick Take & Future Outlook

Chai Discovery's Series B positions it to launch commercial products in 2026, potentially dominating AI-driven molecular design as biotech integrates more computation—watch for partnerships with big pharma amid trends like multi-modal AI.[2] Chai Research could pursue IPO or acquisition, scaling its platform as conversational AI evolves toward personalized agents, influenced by open-source LLMs and regulatory shifts.

Both exemplify AI's pivot to real-world applications, with Chai Discovery anchoring transformative science and Chai Research fueling everyday interactivity—tying back to their core promise of making advanced tech approachable and engineered.